Stoke Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Stoke Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2023.
  • Stoke Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$29.3M, a 11.8% increase year-over-year.
  • Stoke Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$115M, a 2.01% decline year-over-year.
  • Stoke Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$115M, a 9.98% decline from 2022.
  • Stoke Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$104M, a 21.3% decline from 2021.
  • Stoke Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$86.1M, a 62.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$115M -$10.4M -9.98% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-25
2022 -$104M -$18.3M -21.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-25
2021 -$86.1M -$33M -62.3% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-06
2020 -$53M -$17.4M -48.7% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-10
2019 -$35.7M -$22.9M -179% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-09
2018 -$12.8M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.